SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the publication of a new article1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113 (TransVax™), Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Vical and Astellas Pharma Inc. (TSE:4503) ("Astellas") entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113.
Help employers find you! Check out all the jobs and post your resume.
